AACR 2022 – Affimed shows that 2021 was no fluke

A year after stealing the show with clinical case reports that were not formally part of AACR, Affimed has unveiled a bigger dataset confirming that this had been no mirage. 19 lymphoma patients are now evaluable in a phase 1 trial, and AFM13 has put 17 of them into remission, this year’s AACR heard today.

True, there are important caveats: the single-site, academic-sponsored trial likely lacks the objective rigour of a multicentre, company-backed study, and Affimed’s own approach with AFM13 is somewhat different. But the group will no doubt benefit as the data endorse NK cell engagement, an approach to which it had pivoted in 2019.